ArticleUrologic oncology2019

Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer.

Chethan Ramamurthy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.